Disappointing study results for Foamix Pharmaceuticals By: MarketMinute.com Stock News March 27, 2017 at 18:13 PM EDT Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) reported disappointing results from two Phase 3 clinical trials investigating FMX101 to treat moderate to severe acne sending the stock price plummeting $3.80 to close at $5.30. Related Stocks: Foamix Pharma Ord